Maia Biotechnology Inc (MAIA)

$MAIA My goodness its Hard to ADD up how many WARRANTS these guys have issued themselves ... BUY ONE GET ONE .. Cut the price in half so I can buy on par..... Crazy to buy on these terms ... Besides HAS V ever hit a completion target.? lol

$MAIA Will look to buy back in under $1.00.

$MAIA 🤣🤣

$MAIA 3x the survival rate, sayyy less!! I’m back in. Let’s go $5

$MAIA I’m glad I sold this joker!

$MAIA I thought to post these, its the reason why I invested in MAIA. Partial responses and tumor shrinkage are clearly stronger at 180 mg than 60mg. It demonstrates that THIO is biologically active and effective in a dose-dependent manner.

$MAIA Insider buying on this has me believing something positive coming soon.

$MAIA Loaded up on Friday!!

I have relatives who died by cancer, which is why I like to invest in biotech companies who research and develop cancer treatment. First, I bought $KNTE 20k shares @ $2.53, but this company was merged by $XOMA and off public. They refunded the amount of cash equal that I spent plus CVR, not bad at all. Second, after a long time watching, I finally bought $PMVP 3k shares @ $0.90 and $XLO 4k shares @ $0.67. Both companies have mc up to around $50M and phase 2 clinic trials, but cash on hand is bigger, mc. $PMVP is $185M, while $XLO is $85M. Hope they can safely exit Death Valley. Third, $MAIA data phase 2 looks promised, but cash is too few, around $10M. Keep watching.

$MAIA most biotechs up except this shitco

$MAIA. Is it asking too much that we hold our crumbs for at least a couple days?

$MAIA delayed reaction to yesterdays news. This deserves more love!

$MAIA has anyone found the 2L update with only the 180mg patients? MAIA states the dose level at 180mg is "superior" in terms of response but the graph in the poster presentation is all dose levels combined?

$MAIA gap-up to 2.5-2.6 region? 🙏🏽🔑💸

$MAIA In 3L NSCLC, patients usually don’t respond to anything. Seeing a confirmed partial response after 20 mos has got to be extremely rare. The 2L vs 3L disparity is odd as the response isn’t typically improved down the line. I’m not sure what to think about that, but 3L OS at 17.8 mos in CPI refractory patients is damned impressive and even the 2L data is at or notch above the standard options. I’m loading dips. I’m ready for phase 3.

$SILO Float 4.29M $MAIA 21.15M $IPA 25.36M

$MAIA $CADL Two companies with undeniably superb clinical data. I'm down a little in both investments but not going anywhere

$MAIA MAIA Biotechnology announces new partial response in Phase 2 THIO-101 trial MAIA Biotechnology announced a new partial response was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine, sequenced with Regeneron's immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who are resistant to immune therapy and chemotherapy. A partial response is defined as a decrease in tumor size of at least 30%. "The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment. Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC, where the prognosis for the advanced-stage of the disease is typically poor," said CEO Vlad Vitoc. "We confirmed this response with a second scan, and we are highly confident that ateganosine could become an outstanding therapeutic alternative for third-line NSCLC patients." THIO-101 third line data cutoff from May 15, showed median overall survival of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine in parts A and B of the trial. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.

$MAIA MAIA Biotechnology shares are trading higher after the company announced a new partial response was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine, sequenced with Regeneron's immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who are resistant to immune therapy and chemotherapy.

$MAIA Beginning a position with small adds. Looks to have potential for a bounce. Will add larger as she gains strength.

$MAIA 🚨 MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer